Short-term efficacy of tricyclic antidepressants revisited: A meta-analytic study

European Neuropsychopharmacology

Volumn 11, Issue 2, 2001, Pages 173-180

  Storosum, J G ^a   Elferink, A J A ^a   Van Zwieten, B J ^a   Van den Brink, W ^a   Gersons, B P R ^a   Van Strik, R ^a   Broekmans, A W ^a  

^a MEDICINES EVALUATION BOARD   (Netherlands)

Author keywords

Major depression; Meta analysis; Placebo; Tricyclic antidepressants

Indexed keywords

ANTIDEPRESSANT AGENT; IMIPRAMINE; PLACEBO; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PRIORITY JOURNAL; RATING SCALE;

ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT DROPOUTS; PSYCHIATRIC STATUS RATING SCALES; TIME FACTORS;

EID: 0035055164     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(01)00083-9     Document Type: Article

References (12)

1. Confidence intervals for the number needed to treat
2. Hamilton Depression Rating Scale. Extracted from regular and change versions of the schedule for affective disorders and schizophrenia
3. A rating scale for depression
4. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials. An analysis of the Food and Drug Administration database
5. The treatment of depressive states with G-22355 (imipramine hydrochloride)
6. An assessment of clinically useful measures of the consequences of treatment
7. Clinical relevance of response and improvement in psychopharmacology. A statement from the European College of Neuropsychopharmacology, from an ECNP workshop, Jerusalem, October 1995
8. The continuing unethical use of placebo controls